Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more
Sana Biotechnology Inc (SANA) - Total Assets
Latest total assets as of December 2025: $416.89 Million USD
Based on the latest financial reports, Sana Biotechnology Inc (SANA) holds total assets worth $416.89 Million USD as of December 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Sana Biotechnology Inc - Total Assets Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Sana Biotechnology Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Sana Biotechnology Inc's total assets of $416.89 Million consist of 35.7% current assets and 64.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 17.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $59.20 Million | 14.2% |
| Goodwill | $140.63 Million | 33.7% |
Asset Composition Trend (2018–2025)
This chart illustrates how Sana Biotechnology Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Sana Biotechnology Inc's current assets represent 35.7% of total assets in 2025, a decrease from 94.9% in 2018.
- Cash Position: Cash and equivalents constituted 17.2% of total assets in 2025, down from 89.2% in 2018.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, an increase from 0.0% in 2018.
- Asset Diversification: The largest asset category is goodwill at 33.7% of total assets.
Sana Biotechnology Inc Competitors by Total Assets
Key competitors of Sana Biotechnology Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Sana Biotechnology Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Sana Biotechnology Inc generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Sana Biotechnology Inc is currently not profitable relative to its asset base.
Sana Biotechnology Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.89 | 3.54 | 27.52 |
| Quick Ratio | 1.89 | 3.54 | 27.52 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $69.95 Million | $ 115.38 Million | $ 932.32 Million |
Sana Biotechnology Inc - Advanced Valuation Insights
This section examines the relationship between Sana Biotechnology Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.53 |
| Latest Market Cap to Assets Ratio | 1.33 |
| Asset Growth Rate (YoY) | -16.8% |
| Total Assets | $416.89 Million |
| Market Capitalization | $555.45 Million USD |
Valuation Analysis
Above Book Valuation: The market values Sana Biotechnology Inc's assets above their book value (1.33 x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Sana Biotechnology Inc's assets decreased by 16.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Sana Biotechnology Inc (2018–2025)
The table below shows the annual total assets of Sana Biotechnology Inc from 2018 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $416.89 Million | -16.79% |
| 2024-12-31 | $501.02 Million | -11.37% |
| 2023-12-31 | $565.30 Million | -31.29% |
| 2022-12-31 | $822.72 Million | -27.15% |
| 2021-12-31 | $1.13 Billion | +54.65% |
| 2020-12-31 | $730.30 Million | +75.89% |
| 2019-12-31 | $415.19 Million | +1109.31% |
| 2018-12-31 | $34.33 Million | -- |